Regulating peritoneal lymphatic drainage and uses therefor

• US 5,158,538 A
• Filed: 02/21/1991
• Issued: 10/27/1992
• Est. Priority Date: 12/28/1988
• Status: Expired due to Term

• Current Assignee: Hospira Incorporated (Pfizer Inc.)
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Shaw, Howard L.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): NOT, DEFINED
• Application Number:
  US07/658,448
• Time in Patent Office: 614 Days
• Field of Search: 604/27-29, 210/645, 210/646
• US Class Current: 604/28
• CPC Class Codes: A61M 1/287 Dialysates therefor

Abstract

A method for blocking lymphatic drainage of the peritoneal cavity of a living mammal by introducing into such cavity particles in the range from about 15 to 150 micron in their shortest cross section which particles are substantially non-toxic and initially substantially water-insoluble. The method can be practiced in combination with peritoneal dialysis or with pharmaceutical agent administration into the peritoneum. Compositions suitable for use in such particle administration are provided.

Claims

1. A method for blocking lymphatic drainage of the peritoneal cavity of a living mammal comprising the step of introducing into said peritoneal cavity an aqueous dispersion of biodegradable, substantially non-toxic, initially substantially water-insoluble particles that slowly become partially or fully dissolved in the peritoneal cavity or in the lymphatic ducts of said mammal, said particles comprised of at least one material selected from the group consisting of polysaccharides, cellulose and cellulose derivatives, fibrous proteins, plasma proteins, dextran, lactin, polypeptides, polyamino acids, polyesters, polyamides, polyanhydrides, poly(ortho ester), polyacrylates, poly(cyano acrylates), polyvinyl pyrrolidone, phospholipids, polystyrene and polymethylmethacrylate, said particles individually having an average size of about 15 to 150 microns in their shortest cross-section wherein the total number of said particles introduced is at least equal to the estimated number of lymphatic stomata in said peritoneal cavity.

2. The method of claim 1 wherein at least some of said particles are coated.

3. The method of claim 1 wherein said dispersion contains from about 10² to 10¹¹ particles.

4. The method of claim 1 wherein the volume of said dispersion so introduced is from about 250 to 3000 milliliters.

5. The method of claim 1 wherein said particles have a particle size distribution of about 35 to 55 microns.

6. The method of claim 1 wherein said particles as initially introduced have a small average size, but which, after the passage of a predetermined time interval, swell to an average size in the range from about 15 to 150 microns.

7. The method of claim 1 wherein said introduction is carried out either before or during a peritoneal dialysis procedure using said peritoneal cavity.

8. The method of claim 1 wherein said introduction is carried out either before or during administration of a pharmaceutical agent to said peritoneal cavity.

9. An improved method for conducting peritoneal dialysis comprising the steps of:

A. introducing into the peritoneal cavity of a living mammal water dispersable, biodegradable, substantially non-toxic, initially substantially water-insoluble particles that slowly become partially or fully dissolved in the peritoneal cavity or in the lymphatic ducts of said mammal, said particles comprised of at least one material selected from the group consisting of polysaccharides, cellulose and cellulose derivatives, fibrous proteins, plasma proteins, dextran, lactin, polypeptides, polyamino acids, polyesters, polyamides, polyanhydrides, poly(ortho esters), polyacrylates, poly(cyano acrylates), polyvinyl pyrrolidone, phospholipids, polystyrene and polymethylmethacrylate, said particles individually having an average size in the range from about 15 to 150 microns in their shortest cross-section wherein the total number of said particles introduced is at least equal to the estimated number of lymphatic stomata in said peritoneal cavity;

B. introducing into said peritoneal cavity a peritoneal dialysis fluid;

C. retaining the resulting mixture of said fluid and said dispersion in said peritoneal cavity for a time period which is at lest sufficient to achieve urea removal from said mammal through said mammal'"'"'s peritoneum and into said resulting mixture in said peritoneal cavity; and

D. removing said resulting mixture from said peritoneal cavity.

10. The method of claim 9 wherein step (A) predeces step (B).

11. The method of claim 9 wherein step (A) and step (B) are practiced concurrently.

12. The method of claim 9 wherein said particles are dispersed in said dialysis fluid prior to said introduction.

13. The method of claim 9 wherein the quantity of said particles so introduced is at least sufficient to reduce the rate of removal of said resulting mixture from said peritoneal cavity through said mammal'"'"'s lymphatic stomata during said retention compared to the quantity of dialysis fluid so removed when no such particles are present.

14. A method for administering a pharmaceutical agent into a living mammal comprising the steps of:

A. introducing into the peritoneal cavity of a living mammal water dispersable, biodegradable, substantially non-toxic, initially substantially water-insoluble particles that slowly become partially or fully dissolved in the peritoneal cavity or in the lymphatic ducts of said mammal, said particles comprised of at least one material selected from the group consisting of polysaccharides, cellulose and cellulose derivatives, fibrous proteins, plasma proteins, dextran, lactin, polypeptides, polyamino acids, polyesters, polyamides, polyanhydrides, poly(ortho esters), polyacrylates, poly(cyano acrylates), polyvinyl pyrrolidone, phospholipids, polystyrene and polymethylmethacrylate, said particles individually having an average size in range from about 15 to 150 microns in their shortest cross section wherein the total number of said particles introduced is at least equal to the estimated number of lymphatic stomata in said peritoneal cavity; and

B. introducing into said peritoneal cavity a pharmaceutical agent in an amount at least sufficient to provide a pharmaceutically effective does of said agent for said mammal;

said pharmaceutical agent being in a form which is absorbable by said mammal through said mammal'"'"'s peritoneum.

15. The method of claim 14 wherein the resulting mixture of said aqueous dispersion and said pharmaceutical agent is retained in said peritoneal cavity for a time at least sufficient to effect at least a partial absorption of said pharmaceutical agent through said mammal'"'"'s peritoneum.

16. The method of claim 15 wherein after said retaining time said resulting mixture is thereafter removed from said peritoneal cavity.

17. The method of claim 14 wherein step (A) precedes step (B).

18. The method of claim 14 wherein step (A) and step (B) are practiced concurrently.

19. The method of claim 18 wherein said aqueous dispersion and said pharmaceutical agent are combined together into a mixture prior to said introduction.

20. The method of claim 14 wherein the quantity of said particles so-introduced is at least sufficient to reduce the rate of drainage of said pharmaceutical agent from said peritoneal cavity through lymphatic stomata therein compared to the rate of drainage of said pharmaceutical agent from said peritoneal cavity through lymphatic stomata therein when said particles are not present in said peritoneal cavity.

21. The method of claim 18 wherein said pharmaceutical agent as so-introduced is in combination with means regulating the rate of release of said pharmaceutical agent into said peritoneal cavity.

22. A composition adapted for introduction into the peritoneal cavity of a living mammal and which, when so-introduced into such a peritoneal cavity as a unit dose, is adapted to reduced lymphatic drainage from such peritoneal cavity, said composition comprising water which has dispersed therein per unit dose from about 10² to 10¹¹ particles which are biodegradable, substantially non-toxic, initially substantially water-insoluble, and slowly become partially or fully dissolved in the peritoneal cavity or int he lymphatic ducts of said mammal, said particles comprises of at least one material selected from the group consisting of polysaccharides, cellulose and cellulose drivatives, fibrous proteins, plasma proteins, dextran, lactin, polypeptides, polyamino acids, polyesters, polyamides, polyanhydrides, poly(ortho ester), polyacrylates, poly(cyano acrylates), polyvinyl pyrrolidone, phospholipids, polystyrene and polymethylmethacrylate, and said particles have an average particle size in the range from about 15 to 150 microns in their shortest cross section.

23. A composition of claim 22 which additionally contains a pharmaceutical agent.

24. A composition of claim 23 which is adapted for use as a peritoneal dialysis fluid.

25. The composition of claim 23 additionally containing means for releasing said pharmaceutical agent at a predetermined controlled rate.